First-in-Class TG2 Inhibitor New Drug
"Providing a Fundamental Treatment Solution"

Huons is undertaking a national project aimed at researching and developing innovative therapies for Crohn's disease, a rare and intractable condition.


On June 23, Huons announced that it had been selected for the "2026 1st National New Drug Development Project - Research on Building an R&D Ecosystem for New Drug Development (Candidate Substances)" led by the National New Drug Development Project Group.


Huons and the National New Drug Development Project Group held a project agreement ceremony for the National New Drug Development Project on the 22nd. Kyungmi Park, Executive Vice President of Research and Development at Huons (third from the left), and Youngmin Park, Director of the National New Drug Development Project Group (fourth from the left), are posing for a commemorative photo with the attendees. Huons

Huons and the National New Drug Development Project Group held a project agreement ceremony for the National New Drug Development Project on the 22nd. Kyungmi Park, Executive Vice President of Research and Development at Huons (third from the left), and Youngmin Park, Director of the National New Drug Development Project Group (fourth from the left), are posing for a commemorative photo with the attendees. Huons

View original image

Over the next two years, Huons will receive government research funding to identify candidate substances for a transglutaminase 2 (TG2) inhibitor-based therapy for fibrostenotic Crohn's disease and advance it to the preclinical stage.


Previous candidate substances under development for Crohn's disease therapies have focused on regulating fibrosis induced by inflammation, but they failed to control the actual progression of fibrosis, resulting in unsuccessful drug development. Huons explained that its TG2 inhibitor under development features a mechanism of action distinct from existing therapies.



Kyungmi Park, Executive Vice President of Research and Development at Huons, stated, "The TG2 inhibitor project aims to deliver a first-in-class innovative new drug that offers a fundamental solution for patients with fibrostenotic Crohn's disease, who currently lack treatment alternatives." She added, "By targeting the progression phase of fibrosis itself—rather than just its outcomes—we will foster the development of a new drug that can compete in the global market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing